Notice
Recent Posts
Recent Comments
일 | 월 | 화 | 수 | 목 | 금 | 토 |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 | 29 | 30 | 31 |
Tags
- CA
- private equity
- acquisition
- cgi korea
- case study
- Acquistion
- OTCBB
- LOI
- hong kong
- nda
- CCB
- Japan
- China
- Investment
- buyout
- Confidential Agreement
- Malaysia
- PEF
- Bank
- Korea M&A
- Letter of intent
- Korea
- securities
- Japan Tobacco
- capital gate
- sk
- taiwan
- Merger
- M&A
- China Construction Bank
Archives
- Today
- Total
Korea M&A Corporation
Eisai’s $3.9 Billion Parachute: MGI Pharma
Eisai said this morning that it’s dropping $3.9 billion in cash to pick up MGI Pharma, a Minnesota-based company that sells cancer drugs. Consider the deal a parachute for the company to wear when it falls off the patent cliff in 2010, as its biggest selling drug, the Alzheimer’s medicine Aricept, loses patent protection. The Japanese drug business has been struggling — prompting the nation’s he..
News/M&A
2007. 12. 15. 08:53